- Olaparib. PARP-1 and PARP-2 inhibitor, Oncolytic.
[作者:Vasiliou, S; Castaner, R; Bolos, J,期刊:Drugs of the Future, 页码:101-105 , 文章类型: Article,,卷期:2009年34-2]
- Olaparib is a potent inhibitor of poly [ADP-ribose] polymerases PARP-1 and PARP-2 that is currently undergoing clinical development for the treatment of BRCA1/2-defective breast, ovarian, pancreatic and colorectal tumors...
- Tosedostat. Aminopeptidase inhibitor, Oncolytic.
[作者:Owen, RT; Castaner, R; Bolos, J,期刊:Drugs of the Future, 页码:115-118 , 文章类型: Article,,卷期:2009年34-2]
- Tosedostat (CHR-2797) is on orally active aminopeptidase inhibitor that is converted in vivo to a pharmacologically active metabolite, CHR-79888, and exerts on antiproliferative effect against a wide range of leukemic an...
- GAUCHER'S DISEASE
[作者:Dulsat, C; Mealy, N,期刊:Drugs of the Future, 页码:147-149 , 文章类型: Article,,卷期:2009年34-2]
- Approved treatments for the lysosomal storage syndrome Gaucher's disease include enzyme replacement therapy (imiglucerase, Cerezyme (R); Genzyme Therapeutics) and substrate inhibition therapy (miglustat, Zavesca (R); Act...
- THERAPEUTIC TARGETS FOR BIPOLAR DISORDER
[作者:Sorbera, LA; Dulsat, C; Rosa, E,期刊:Drugs of the Future, 页码:151-158 , 文章类型: Article,,卷期:2009年34-2]
- Bipolar disorder is a psychiatric illness characterized by aromatic mood swings in which on individual experiences periods of highs (euphoria) and lows (sadness), referred to as episodes of mania and depression, respecti...
|